American association of cancer research highlights article published by PHI collaborators

In the October issue of Molecular Cancer Therapeutics the American Association of Cancer Research (AACR) highlights the novel nano­medicine against ovarian cancer developed by scientists from the Center for Pharma­ceutical Bio­tech­nology and Nano­medicine at North­eastern University. PHI maintains the Holographic Imaging Cytometry Program of Excellence at the University since 2014. For more information about the article see dx.doi.org/10.1158/1535-7163.MCT-15-0986.

Ovarian cancer is the deadliest gynecologic malignancy in developed countries. It has a 5-year survival rate of approximately 40% and accounts for 6% of all cancer-related deaths in women in the United States. A combination chemotherapy prolongs the lives of patients. However, the disease recurs in 80% of cases because the tumor cells develop drug resistance.

Using HoloMonitor® M4 the researchers at the University of Chicago and Northeastern University have shown that the new treatment prevents recurring tumor growth by stopping drug resistant cells from dividing.

A HoloMonitor M4 time-lapse sequence of a treated drug resistant ovarian cancer cell which starts to divide but fail.

“In total, our customers and partners have published over 60 scientific pub­lica­tions where the company’s technology has been used. The publications, which are reviewed by inde­pen­dent scientists, show the scientific value of our HoloMonitor technology and thereby its market potential in cancer research and other bioscience applications”, said CEO Peter Egelberg.

A list of the scientific publications can be found here.